Last reviewed · How we verify
Metronidazole Vaginal
Metronidazole is a nitroimidazole antimicrobial that disrupts bacterial and protozoal DNA, leading to cell death.
Metronidazole is a nitroimidazole antimicrobial that disrupts bacterial and protozoal DNA, leading to cell death. Used for Bacterial vaginosis, Trichomoniasis vaginalis infection, Anaerobic vaginal infections.
At a glance
| Generic name | Metronidazole Vaginal |
|---|---|
| Also known as | Metronidazole Suppositories, MetroGel, Vandazole |
| Sponsor | Peking University Shenzhen Hospital |
| Drug class | Nitroimidazole antimicrobial |
| Target | Bacterial/protozoal DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is reduced by anaerobic organisms to form reactive intermediates that damage DNA and inhibit nucleic acid synthesis. It is effective against anaerobic bacteria and certain protozoa. The vaginal formulation delivers the drug locally to treat vaginal infections caused by susceptible organisms.
Approved indications
- Bacterial vaginosis
- Trichomoniasis vaginalis infection
- Anaerobic vaginal infections
Common side effects
- Vaginal irritation or burning
- Metallic taste
- Headache
- Vulvovaginal candidiasis (secondary infection)
Key clinical trials
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (NA)
- Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial (PHASE2)
- Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients (PHASE2)
- Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa） (PHASE2)
- Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies (NA)
- Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole (NA)
- Vaginal Microbiota Transplant (PHASE1, PHASE2)
- A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole Vaginal CI brief — competitive landscape report
- Metronidazole Vaginal updates RSS · CI watch RSS
- Peking University Shenzhen Hospital portfolio CI